Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization.
Pombo Antunes AR, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, Kancheva D, Martens L, De Vlaminck K, Van Hove H, Kjølner Hansen SS, Bosisio FM, Van der Borght K, De Vleeschouwer S, Sciot R, Bouwens L, Verfaillie M, Vandamme N, Vandenbroucke RE, De Wever O, Saeys Y, Guilliams M, Gysemans C, Neyns B, De Smet F, Lambrechts D, Van Ginderachter JA, Movahedi K. Pombo Antunes AR, et al. Among authors: neyns b. Nat Neurosci. 2021 Apr;24(4):595-610. doi: 10.1038/s41593-020-00789-y. Epub 2021 Mar 29. Nat Neurosci. 2021. PMID: 33782623
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B. Sadones J, et al. Among authors: neyns b. Eur J Cancer. 2009 Jan;45(1):146-53. doi: 10.1016/j.ejca.2008.09.002. Epub 2008 Oct 20. Eur J Cancer. 2009. PMID: 18945611
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B. Lv S, et al. Among authors: neyns b. Int J Oncol. 2012 Sep;41(3):1029-35. doi: 10.3892/ijo.2012.1539. Epub 2012 Jun 29. Int J Oncol. 2012. PMID: 22752145 Clinical Trial.
Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma.
Duerinck J, Clement PM, Bouttens F, Andre C, Neyns B, Staelens Y, Van Fraeyenhove F, Baurain JF, Luce S, D'hondt L, Joosens E, Specenier P, Verschaeve V, Filleul B, Vroman P, Stragier B, Rogiers A. Duerinck J, et al. Among authors: neyns b. J Neurol. 2015 Mar;262(3):742-51. doi: 10.1007/s00415-014-7633-z. Epub 2015 Jan 9. J Neurol. 2015. PMID: 25572162
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Duerinck J, Du Four S, Vandervorst F, D'Haene N, Le Mercier M, Michotte A, Van Binst AM, Everaert H, Salmon I, Bouttens F, Verschaeve V, Neyns B. Duerinck J, et al. Among authors: neyns b. J Neurooncol. 2016 May;128(1):147-155. doi: 10.1007/s11060-016-2092-2. Epub 2016 Mar 2. J Neurooncol. 2016. PMID: 26935577 Clinical Trial.
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Du Four S, Maenhout SK, Benteyn D, De Keersmaecker B, Duerinck J, Thielemans K, Neyns B, Aerts JL. Du Four S, et al. Among authors: neyns b. Cancer Immunol Immunother. 2016 Jun;65(6):727-40. doi: 10.1007/s00262-016-1836-3. Epub 2016 Apr 20. Cancer Immunol Immunother. 2016. PMID: 27098427 Free PMC article. Clinical Trial.
223 results